LENZ Therapeutics, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
LENZ Therapeutics reported Q2 2026 total revenue of $5.5M ($1.7M product sales from ~27,000 packs; $3.8M license revenue). Product sales grew 9% sequentially. The company achieved five new international milestones: Arrotex (Australia/New Zealand) upfront + mid-double-digit margin share; Laboratoires Théa (Canada) $65M remaining milestones + double-digit royalties; Everest/CORXEL (Greater China) $85M remaining milestones + mid-to-low double-digit royalties; Lunatus (Saudi Arabia) MAA submission. Cash position: $220M. Net loss H1 2026: $73.4M ($2.34/share) vs. $29.5M H1 2025 ($1.06/share), driven by $84.3M SG&A (6x prior year).
Why this rating
Early commercial traction (60% refill, 5 packs/yr cohorts) offset by steep cash burn; $220M cash sufficient, but H1 burn ~$73M/quarter. Milestone/royalty upside material long-term; near-term revenue minimal vs. company scale.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.